-

TheracosBio Announces Royalty Financing Agreement with HealthCare Royalty

MARLBOROUGH, Mass.--(BUSINESS WIRE)--TheracosBio today announced that its consolidated group of companies has signed a royalty financing agreement with HealthCare Royalty (HCRx). Under the terms of the agreement, HCRx will be entitled to a portion of the future royalties and milestone payments from the commercialization of a veterinary product developed by TheracosBio and commercialized by Elanco Animal Health. In exchange, the TheracosBio group received an upfront cash payment.

Last month, TheracosBio announced the commercial launch of Brenzavvy™ (bexagliflozin), its FDA-approved SGLT2 inhibitor.

“This financing is a tremendous asset for TheracosBio at a pivotal time for the company,” said Brian Connelly, President and CEO of TheracosBio. “This agreement further allows us to scale the distribution of Brenzavvy and ensure that it is available at an affordable price for adult patients in the US.”

About TheracosBio

TheracosBio develops novel therapeutics for diseases with significant societal impact. The mission of TheracosBio is to expand access to new medications for patients with common diseases.

About HealthCare Royalty

HCRx is a leading royalty acquisition company focused on commercial or near-commercial stage biopharmaceutical products. HCRx has $6.3 billion in cumulative capital commitments with offices in Stamford (CT), San Francisco, Boston and London. For more information, visit www.hcrx.com. HEALTHCARE ROYALTY® and HCRx® are registered trademarks of HealthCare Royalty Management, LLC.

Contacts

Media Contact
Lauren Arnold
MacDougall Advisors
1 (617) 694-5387
larnold@macdougall.bio

TheracosBio


Release Summary
TheracosBio today announced a royalty financing agreement with HealthCare Royalty (HCRx).
Release Versions

Contacts

Media Contact
Lauren Arnold
MacDougall Advisors
1 (617) 694-5387
larnold@macdougall.bio

More News From TheracosBio

TheracosBio and SmithRx Collaborate to Offer Newly Approved Diabetes Drug Brenzavvy™ (bexagliflozin) to Members with Type 2 Diabetes

MARLBOROUGH, Mass. & SAN FRANCISCO--(BUSINESS WIRE)--TheracosBio and SmithRx announce collaboration expanding access to BRENZAVVY™ (bexagliflozin) through Mark Cuban Cost Plus Drug Company....

TheracosBio Announces Publication of Data on the Safety and Effectiveness of Brenzavvy™ (bexagliflozin) as an Adjunct to Metformin

MARLBOROUGH, Mass.--(BUSINESS WIRE)--TheracosBio today announced the publication of a study titled “Bexagliflozin as an Adjunct to Metformin for the Treatment of Type 2 Diabetes in Adults: a 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial” in Diabetes, Obesity and Metabolism. The Phase 3 study assessed the safety and effectiveness of Brenzavvy™ (bexagliflozin), 20 mg, in adults with type 2 diabetes mellitus as an adjunct to metformin, as compared to placebo. The study results showed...

TheracosBio Appoints Brian Connelly as Chief Executive Officer

MARLBOROUGH, Mass.--(BUSINESS WIRE)--TheracosBio announces the appointment of Brian Connelly as President and Chief Executive Officer....
Back to Newsroom